ARTICLE | Clinical News
Coley ProMune Phase II NSCLC data
May 17, 2005 2:08 AM UTC
Coley (Wellesley, Mass.) said data from a Phase II trial of ProMune ( CPG 7909) plus chemotherapy to treat non-small cell lung cancer (NSCLC) showed that the combination gave a 37% tumor response rate...